Friday, December 9, 2022 | Back issues
Courthouse News Service Courthouse News Service

Medical Merger

Shareholders claim in a federal class action that directors of The Medicines Company made false and misleading statements to support its sale to Novartis for $85 per share or $9.7 billion.

WILMINGTON, Del. — Shareholders claim in a federal class action that directors of The Medicines Company made false and misleading statements to support its sale to Novartis for $85 per share or $9.7 billion.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...